Alvotech to Manufacture Prestige's Biosimilars

Iceland-based Alvotech and Singapore-based Prestige Biopharma have entered a contract manufacturing partnership for Prestige’s biosimilars.

Under the partnership, Alvotech will be responsible for commercial production at its new Reykjavik facility, where it will scale up and perform process validation.

Mark Levick, Alvotech’s chief executive officer, said in a statement that the partnership “marks an important milestone for our company as we work towards expanding our contract manufacturing business. We are pleased to be trusted with the responsibility of delivering high quality manufacturing services to Prestige Biopharma and look forward to further collaboration in the future. We pride ourselves on delivering highest quality commercial production from one of the best biopharma facilities in the world.”

The deal is the latest in a string of agreements related to biosimilars for Prestige, which in July entered into an exclusive agreement with Pharmapark LLC to supply and commercialize Prestige’s trastuzumab biosimilar, HD201, in Russia.

The Pharmapark deal came on the heels of an agreement with Mundipharma to license and supply the same biosimilar in parts of Europe.

In 2018, Prestige announced entered into a licensing agreement with Cipla Limited to distribute and market the biosimilar trastuzumab in some emerging markets, and even earlier, Prestige inked a deal with Alvogen to commercialize the biosimilar in Central and Eastern Europe.

In May of this year, the European Medicines Agency accepted for review a Marketing Authorization Application for HD201, and the company is also developing biosimilars referencing bevacizumab, adalimumab, denosumab, aflibercept, eculizumab, and ipilimumab.